T 1806/18 (Nilotinib for treating chronic myeloid leukemia / NOVARTIS) of 21.10.2021
- European Case Law Identifier
- ECLI:EP:BA:2021:T180618.20211021
- Date of decision
- 21 October 2021
- Case number
- T 1806/18
- Petition for review of
- -
- Application number
- 10781781.9
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R KINASE ACTIVITY
- Applicant name
- Novartis AG
- Opponent name
- Fresenius Kabi Deutschland GmbH
Hamm&Wittkopp Patentanwälte PartmbB
TEVA PHARMACEUTICAL INDUSTRIES, LTD.
Intas Pharmaceuticals Ltd.
Generics (U.K.) Limited - Board
- 3.3.01
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 54European Patent Convention Art 56Rules of procedure of the Boards of Appeal 2020 Art 013(2)Rules of procedure of the Boards of Appeal Art 12(4)
- Keywords
- Main request - novelty (yes)
Main request - inventive step - reasonable expectation of success (no)
Late-filed documents
Late-filed document - admitted (no) - Catchword
- -
- Citing cases
- T 0136/24
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The patent is remitted to the opposition division with the order to maintain the patent with the following claims and a description to be adapted thereto:
claims 1 and 2 of the main request filed by letter dated 21 February 2018